Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02, Bloomberg Earnings reports.
Shares of Aldeyra Therapeutics (NASDAQ:ALDX) traded down 1.16% during trading on Friday, hitting $4.25. The company had a trading volume of 7,783 shares. The stock’s 50-day moving average price is $4.65 and its 200 day moving average price is $4.74. The company’s market capitalization is $26.54 million. Aldeyra Therapeutics has a 52 week low of $3.80 and a 52 week high of $8.19.
In related news, major shareholder Life Sciences Maste Perceptive purchased 296,007 shares of the stock in a transaction that occurred on Friday, June 30th. The shares were purchased at an average price of $4.60 per share, with a total value of $1,361,632.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.40% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the stock. Virtu KCG Holdings LLC acquired a new stake in shares of Aldeyra Therapeutics during the second quarter worth $104,000. Renaissance Technologies LLC acquired a new stake in shares of Aldeyra Therapeutics during the first quarter worth $132,000. Hikari Power Ltd purchased a new stake in shares of Aldeyra Therapeutics during the first quarter valued at approximately $188,000. Sabby Management LLC purchased a new stake in shares of Aldeyra Therapeutics during the first quarter valued at approximately $898,000. Finally, Vanguard Group Inc. raised its stake in shares of Aldeyra Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after buying an additional 9,407 shares during the period. 58.20% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Rincon Hill News and is owned by of Rincon Hill News. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://rinconhillneighbors.org/2017/08/19/aldeyra-therapeutics-inc-nasdaqaldx-issues-quarterly-earnings-results-updated.html.
A number of research analysts have weighed in on ALDX shares. Zacks Investment Research lowered Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. HC Wainwright set a $18.00 price objective on Aldeyra Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Canaccord Genuity set a $12.00 price objective on Aldeyra Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 14th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $16.00 price objective on shares of Aldeyra Therapeutics in a research report on Wednesday, May 31st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $14.15.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with our FREE daily email newsletter.